MOGAMULIZUMAB for Cutaneous t-cell lymphoma stage iv: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 11 adverse event reports in the FDA FAERS database where MOGAMULIZUMAB was used for Cutaneous t-cell lymphoma stage iv.
Most Reported Side Effects for MOGAMULIZUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Rash | 59 | 13.4% | 13 | 25 |
| Disease progression | 46 | 10.4% | 22 | 20 |
| Infusion related reaction | 42 | 9.5% | 22 | 25 |
| Pyrexia | 35 | 7.9% | 19 | 25 |
| Febrile neutropenia | 29 | 6.6% | 19 | 14 |
| Erythema | 28 | 6.4% | 9 | 12 |
| Pruritus | 26 | 5.9% | 1 | 5 |
| Drug ineffective | 24 | 5.4% | 8 | 9 |
| Constipation | 22 | 5.0% | 10 | 18 |
| Death | 21 | 4.8% | 21 | 2 |
| Insomnia | 21 | 4.8% | 14 | 10 |
| White blood cell count decreased | 21 | 4.8% | 11 | 10 |
| Diarrhoea | 19 | 4.3% | 7 | 9 |
| Anaemia | 17 | 3.9% | 8 | 7 |
| Decreased appetite | 17 | 3.9% | 6 | 7 |
Other Indications for MOGAMULIZUMAB
Product used for unknown indication (118)
Adult t-cell lymphoma/leukaemia (115)
Cutaneous t-cell lymphoma (94)
Peripheral t-cell lymphoma unspecified (17)
Angioimmunoblastic t-cell lymphoma (7)
Tropical spastic paresis (7)
Peripheral t-cell lymphoma unspecified recurrent (6)
Hepatocellular carcinoma (5)
Other Drugs Used for Cutaneous t-cell lymphoma stage iv
MOGAMULIZUMAB-KPKC (58)
BEXAROTENE (9)
METHOTREXATE (9)
GEMCITABINE (8)
BRENTUXIMAB VEDOTIN (7)
CYCLOPHOSPHAMIDE (7)
DOXORUBICIN (6)
PRALATREXATE (6)
VORINOSTAT (6)
METHOXSALEN (5)